Tonix Pharmaceuticals Holding

Tonix Pharmaceuticals Holding develops pharmaceutical products for central nervous system disorders.

Tonix Pharmaceuticals Holding Corp., a development stage specialty pharmaceutical company, focuses on the development of pharmaceutical products for the disorders of central nervous system. The company’s lead product candidate includes TNX-102 SL, a dose and formulation of cyclobenzaprine for the treatment of fibromyalgia and post-traumatic stress disorder. It also has a pipeline of various other product candidates, including TNX-201, which is a treatment for certain types of headaches; and TNX-301. The company was founded in 2007 and is headquartered in New York, New York.